Literature DB >> 19720547

Basic principles of stability.

William Egan1, Timothy Schofield.   

Abstract

An understanding of the principles of degradation, as well as the statistical tools for measuring product stability, is essential to management of product quality. Key to this is management of vaccine potency. Vaccine shelf life is best managed through determination of a minimum potency release requirement, which helps assure adequate potency throughout expiry. Use of statistical tools such a least squares regression analysis should be employed to model potency decay. The use of such tools provides incentive to properly design vaccine stability studies, while holding stability measurements to specification presents a disincentive for collecting valuable data. The laws of kinetics such as Arrhenius behavior help practitioners design effective accelerated stability programs, which can be utilized to manage stability after a process change. Design of stability studies should be carefully considered, with an eye to minimizing the variability of the stability parameter. In the case of measuring the degradation rate, testing at the beginning and the end of the study improves the precision of this estimate. Additional design considerations such as bracketing and matrixing improve the efficiency of stability evaluation of vaccines.

Mesh:

Substances:

Year:  2009        PMID: 19720547     DOI: 10.1016/j.biologicals.2009.08.012

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  4 in total

1.  Correlation Study of the Most Important Environmental Influencing Factors on the Razi MMR Vaccine.

Authors:  S Soleimani; S Rashid
Journal:  Arch Razi Inst       Date:  2021-11-30

2.  Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine.

Authors:  Ahd Hamidi; Femke Hoeksema; Pim Velthof; Angelique Lemckert; Gert Gillissen; Alfred Luitjens; Julie E Bines; Swathi R Pullagurla; Prashant Kumar; David B Volkin; Sangeeta B Joshi; Menzo Havenga; Wilfried A M Bakker; Christopher Yallop
Journal:  Vaccine       Date:  2021-03-18       Impact factor: 3.641

3.  Long-term stability predictions of therapeutic monoclonal antibodies in solution using Arrhenius-based kinetics.

Authors:  Drago Kuzman; Marko Bunc; Miha Ravnik; Fritz Reiter; Lan Žagar; Matjaž Bončina
Journal:  Sci Rep       Date:  2021-10-15       Impact factor: 4.379

4.  Potency testing for a recombinant protein vaccine early in clinical development: Lessons from the Schistosoma mansoni Tetraspanin 2 vaccine.

Authors:  Guangzhao Li; Lara Hoeweler; Brian Keegan; Jin Peng; Larissa Scholte; Peter Hotez; Maria Elena Bottazzi; David Diemert; Jeffrey Bethony
Journal:  Vaccine X       Date:  2021-06-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.